NOTICE OF MEETING AND AGENDA
Communication and Public Education Committee
September 18, 2014

Contact Person: Laura Hendricks
(916) 574-7918

This committee meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Laura Hendricks at (916) 574-7918, by emailing laura.hendricks@dca.ca.gov or sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA 95834. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

DATE: September 18, 2014
PLACE: Department of Consumer Affairs
1625 N. Market Blvd., 1st Floor Hearing Room
Sacramento, CA 95834

NOTE: Pharmacists and pharmacy technicians who attend in person may be awarded 2 hours of CE, in accordance with the Board’s CE policy. Sign in and sign out on the day of the meeting will be required for the CE credit.

For verification of the meeting, call (916) 574-7918 or (916) 574-7900 or access the Board’s Web site at www.pharmacy.ca.gov.

Discussion and action may be taken on any item on the agenda. Opportunities are provided for public comment on each agenda item. A quorum of the board may be present at committee meetings. Board members who are not on the committee may observe, but may not participate as a committee member or vote. All times are approximate and subject to change.
Call to Order                                                                                                                       11  a.m.

1. Discussion concerning the parameters for patient consultation as required by 16CCR Section 1707.2

2. Resumption of the Committee’s Assessment of California’s Patient-Centered Labeling Requirement
   a. Should Section 1707.5(a)(1)(B) Require Listing of the Manufacturer’s Name in the Patient-Centered Clustered Area of the Label When a Generic Drug Is Dispensed?
   b. When a Generic Drug Is Dispensed, Should the Brand Name of the Generic Equivalent Be Included on the Label Phrased as “Generic for ______”? 
   c. Should Purpose or Condition Be a General Requirement for Labels?
   d. Should the Existing Requirements for “Added Emphasis” in the Patient-Centered Area of the Prescription Label Be Modified?
   e. Translations on Labels:
      1. Translated Directions for Use Are Available on the Board’s Website. Should the Board Require Use of Them to Aid Patients with Limited English Proficiency?
      2. Should There Be a Specific Requirement for Labels to Be Translated? If So, What Components Are Needed (e.g., Also printed in English, Only Directions, and Exemption from Liability for Translation Errors)?
   f. Should the Board Adopt Liquid Measurement Standards as recommended by NCPDP?
   g. Should the Board Consider Technology Standards to Enhance the Patient-Centered label?

3. Development of the Draft of a Board Policy Statement Recommending the Elimination of Tobacco and E-Cigarette Sales from California Pharmacies

4. Update on The Script

5. Update on the Board’s Consumer Education Brochure on Counterfeit Drugs

6. Public Continuing Education Training Session by the California State Board of Pharmacy and Department of Justice Held September 2 and 3, 2014, in Santa Barbara
7. Update on Media Activity

8. Public Outreach Activities Conducted by the Board

9. Review and Discussion of Articles on Issues of Interest


11. Public Comment for Items Not on the Agenda, Matters for Future Meetings*

*(Note: the committee may not discuss or take action on any matter raised during the public comment section that is not included on this agenda, except to decide to place the matter on the agenda of a future meeting. Government Code Sections 11125 and 11125.7(a))

Adjournment 3 p.m.